# Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

Study · id `cardio:ct-nct03624881` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03624881](<https://clinicaltrials.gov/study/NCT03624881>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03624881

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 333 participants.

## Technical summary

Registry record NCT03624881. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-04 (actual); primary completion 2021-06-28 (actual). Results posted on 2022-09-07.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 333 participants (enrolled count; ClinicalTrials.gov record NCT03624881, source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)
- Started: 2018-09-04 (actual) (ClinicalTrials.gov record NCT03624881, source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)
- Primary completion: 2021-06-28 (actual) (ClinicalTrials.gov record NCT03624881, source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)
- Completion: 2021-06-28 (actual) (ClinicalTrials.gov record NCT03624881, source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)
- Results first posted: 2022-09-07 (ClinicalTrials.gov record NCT03624881, source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03624881, source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03624881-2023-07-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): Catheter ablation with EPU
- Lead sponsor: Biosense Webster, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: ceecf1566c65a59d301fb036f9cf09ebefe7a7741ef63c82ce7fac1990212c42
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
